Nurix Therapeutics, Inc. (NRIX) stock
Close on Nov 11, 2026Market cap $1.78BP/E 7.1Yield 0.00%
Nurix Therapeutics, Inc. grew revenue 738.8% to $701.94M over the twelve months to Aug 31, 2026. Free cash flow was $369.81M. At the latest close the market valued the company at $1.78B, 7.1 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Aug 31, 2026
Valuation
- Market cap
- $1.78B
- P/E ratio
- 7.1
- Price to sales
- 2.54
- Price to book
- 1.84
- Dividend yield
- 0.00%
- Free cash flow yield
- 20.73%
Fundamentals
- Revenue
- $701.94M
- Net income
- $294.88M
- EPS, diluted
- $2.31
- Free cash flow
- $369.81M
- Book value per share
- $8.34
- Diluted shares
- 116M
Trading
- Next earnings
- Jan 27, 2027 (estimated, after the close)
- Previous close
- $15.88
- Open
- $16.00
- Day's range
- $15.91 – $16.70
- Volume
- 2,979,929
- Average volume (20 days)
- 4,171,007
- Index membership
- Russell 2000 (since Sep 2020), Russell 3000 (since Aug 2020)
- Beta (5 years)
- 1.47
- 52-week range
- $12.01 – $28.23
- RSI (14 days)
- 28.6
- Volatility (1 year)
- 67.4%
- Relative volume
- 1.49×
- WACC
- 12.2%
On 3 of our idea lists: More cash than they're worth, Undervalued and financially sound, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | NRIX | S&P 500 | Difference | NRIX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -26.9% | -2.4% | −24.5 pts | ||
| 3 months | -37.1% | -1.2% | −35.9 pts | ||
| Year to date | -13.9% | +12.3% | −26.2 pts | ||
| 1 year | +27.0% | +12.4% | +14.5 pts | ||
| 3 years | +209.9% | +78.8% | +131.1 pts | +45.8% | +21.4% |
| 5 years | -50.6% | +75.2% | −125.8 pts | -13.2% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Nurix Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Update
- Results
About Nurix Therapeutics
Pharmaceutical Preparations
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company that discovers and develops targeted protein degradation medicines for cancer and inflammatory diseases. Its clinical drug pipeline features bexobrutideg, a Bruton's tyrosine kinase degrader; zelebrudomide, a dual degrader of kinase and transcription factors; and NX-1607, a CBL-B inhibitor. The company also creates preclinical degraders and degrader antibody conjugates. Nurix aims to treat patients with unmet medical needs, while collaborating with biopharmaceutical companies, including Gilead Sciences, Sanofi, and Pfizer, to advance partnered discovery programs.
Company profile, executives and historyNurix Therapeutics stock: common questions
What is Nurix Therapeutics's stock price?
NRIX closed at $16.33 on Nov 11, 2026, up 2.83% on the day. Over the past 52 weeks it traded between $12.01 and $28.23.
What is Nurix Therapeutics's market cap?
Nurix Therapeutics was worth $1.78B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is NRIX's P/E ratio?
NRIX trades at 7.1 times earnings, based on diluted earnings per share of $2.31 over the twelve months to Aug 31, 2026.
How much revenue does Nurix Therapeutics make?
Nurix Therapeutics reported revenue of $701.94M for the twelve months to Aug 31, 2026, up 738.8% from a year earlier.
Does Nurix Therapeutics pay a dividend?
No. Nurix Therapeutics has not paid a cash dividend over the last twelve months.
When does Nurix Therapeutics report earnings next?
Nurix Therapeutics is expected to report Q4 FY2026 results on Jan 27, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has NRIX stock performed over the past year?
Including dividends, NRIX returned +27.0% over the past year, against +12.4% for the S&P 500.
How many NRIX shares are sold short?
19M shares were sold short at the latest FINRA report, 17.90% of the float, or 7.2 days of average trading volume.
Who are Nurix Therapeutics's competitors?
Companies most similar to Nurix Therapeutics by business, industry and size include ARVN, PTGX, RARE, HCM, MIRM.
See a number that looks wrong?